Analytical Data
-
Gene name
EP4
- Application
-
Alternative Names
EP4R; PTGER4; Prostanoid EP4 receptor; Prostaglandin E2 receptor EP4 subtype
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P35408
-
Expression Region
Arg333~Ile488
-
Molecular Weight
50kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EP4 (Prostaglandin E receptor 4) is a crucial member of the prostaglandin receptor family, playing a significant role in various physiological and pathological processes, including inflammation, cancer progression, and immune response. Research into EP4 has gained momentum due to its involvement in modulating immune cell functions and promoting tumor growth, making it a potential therapeutic target for various diseases. The EP4 receptor is activated by prostaglandin E2 (PGE2), and its activation leads to diverse cellular responses through downstream signaling pathways, including cyclic AMP production and modulation of gene expression. Recent studies have focused on the development of EP4 antagonists that can inhibit its pathway, presenting promising avenues for drug discovery against diseases characterized by excessive inflammation or tumorigenesis. Additionally, the production of recombinant EP4 proteins has become essential for studying its structure, function, and interactions with ligands and other cellular components. These recombinant proteins serve as valuable tools for elucidating the mechanistic insights into EP4 signaling and pharmacology, ultimately facilitating the advancement of novel therapeutic strategies targeting EP4 for improved healthcare outcomes.
